Detalhe da pesquisa
1.
CAR T-cell therapy induces a high rate of prolonged remission in relapsed primary CNS lymphoma: Real-life results of the LOC network.
Am J Hematol
; 99(7): 1240-1249, 2024 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-38586986
2.
Combining MYD88 L265P mutation detection and clonality determination on CSF cellular and cell-free DNA improves diagnosis of primary CNS lymphoma.
Br J Haematol
; 201(6): 1088-1096, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36941788
3.
A fixed-duration, measurable residual disease-guided approach in CLL: follow-up data from the phase 2 ICLL-07 FILO trial.
Blood
; 137(8): 1019-1023, 2021 02 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-33167024
4.
Identification of 2 DNA methylation subtypes of Waldenström macroglobulinemia with plasma and memory B-cell features.
Blood
; 136(5): 585-595, 2020 07 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-32457988
5.
Isolated intraocular relapses of primary cerebral lymphomas: An LOC network study.
Hematol Oncol
; 40(5): 976-986, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-35789106
6.
Chemotherapy is an efficient treatment in primary CNS MALT lymphoma.
J Neurooncol
; 159(1): 151-161, 2022 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-35725885
7.
Primary vitreoretinal lymphoma: short review of the literature, results of a European survey and French guidelines of the LOC network for diagnosis, treatment and follow-up.
Curr Opin Oncol
; 33(5): 420-431, 2021 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34292201
8.
Genetic characterization of B-cell prolymphocytic leukemia: a prognostic model involving MYC and TP53.
Blood
; 134(21): 1821-1831, 2019 11 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-31527074
9.
Efficacy of minimal residual disease driven immune-intervention after allogeneic hematopoietic stem cell transplantation for high-risk chronic lymphocytic leukemia: results of a prospective multicenter trial.
Haematologica
; 106(7): 1867-1875, 2021 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32527951
10.
Plasmacytoid dendritic cells proliferation associated with acute myeloid leukemia: phenotype profile and mutation landscape
Haematologica
; 106(12): 3056-3066, 2021 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33054115
11.
Intravenous high-dose methotrexate based systemic therapy in the treatment of isolated primary vitreoretinal lymphoma: An LOC network study.
Am J Hematol
; 96(7): 823-833, 2021 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33864703
12.
Primary CNS lymphoma patient-derived orthotopic xenograft model capture the biological and molecular characteristics of the disease.
Blood Cells Mol Dis
; 75: 1-10, 2019 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30502564
13.
Standardization of Flow Cytometric Immunophenotyping for Hematological Malignancies: The FranceFlow Group Experience.
Cytometry A
; 95(9): 1008-1018, 2019 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-31364809
14.
CAR T-cell therapy in primary central nervous system lymphoma: the clinical experience of the French LOC network.
Blood
; 139(5): 792-796, 2022 02 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34871363
15.
Optimization of CSF biological investigations for CNS lymphoma diagnosis.
Am J Hematol
; 94(10): 1123-1131, 2019 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31328307
16.
Direct-Acting Antiviral Therapy Restores Immune Tolerance to Patients With Hepatitis C Virus-Induced Cryoglobulinemia Vasculitis.
Gastroenterology
; 152(8): 2052-2062.e2, 2017 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-28274850
17.
CAR T-cell therapy for central nervous system lymphomas: blood and cerebrospinal fluid biology, and outcomes.
Haematologica
; 108(12): 3485-3490, 2023 Dec 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37345469
18.
"Double-hit" chronic lymphocytic leukemia: An aggressive subgroup with 17p deletion and 8q24 gain.
Am J Hematol
; 93(3): 375-382, 2018 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-29194741
19.
Temozolomide is effective and well tolerated in patients with primary vitreoretinal lymphoma.
Blood
; 135(20): 1811-1815, 2020 05 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-32125361
20.
Presence of multiple recurrent mutations confers poor trial outcome of relapsed/refractory CLL.
Blood
; 126(18): 2110-7, 2015 Oct 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-26316624